These results collectively suggest that mucosal gene therapy has the potential to reduce TP53-associated HNSCCs in FA, where its effectiveness will depend on the spread of gene-corrected cells to counteract FA-associated elevated mutation rates and/or selective pressures. The gene discussed is TP53; the disease is Friedreich ataxia.